Ratings aap Implantate AG Xetra

Equities

AAQ

DE0005066609

End-of-day quote Xetra 06:00:00 2024-02-04 pm EST 5-day change 1st Jan Change
0.73 EUR -2.67% Intraday chart for aap Implantate AG -9.32% -12.05%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The company's share price in relation to its net book value makes it look relatively cheap.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
-12.05% 9.68M -
-2.31% 187B
C+
-3.20% 106B
C
-5.04% 66.9B
A
+0.20% 49.45B
B-
+17.29% 48B
B-
+4.06% 40.84B
B+
+2.36% 26.25B
A-
+2.07% 26.48B
B
+12.96% 24.62B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes